Synthesis, characterization, molecular structures, antimicrobial and anti-proliferative activities of thiophene-linked 1,2,4-triazoles and condensed triazoles

被引:0
作者
El-Emam, Nada A. [1 ]
Moustafa, Mohamed A. A. [1 ]
Mohamed, Ahmed A. B. [1 ]
Blacque, Olivier [2 ]
Habib, El-Sayed E. [3 ]
Krishnan, Vignesh [4 ]
Thamotharan, Subbiah [4 ]
El-Ashmawy, Mahmoud B. [1 ]
机构
[1] Mansoura Univ, Fac Pharm, Dept Med Chem, Mansoura 35516, Egypt
[2] Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
[3] Mansoura Univ, Fac Pharm, Dept Microbiol & Immunol, Mansoura 35516, Egypt
[4] SASTRA Deemed Univ, Sch Chem & Biotechnol, Dept Bioinformat, Biomol Crystallog Lab, Thanjavur 613401, India
关键词
4-triazoles; Condensed triazoles; Antimicrobial activity; Anti-proliferative activity; Molecular docking; SELECTIVE INHIBITOR; AMG; 337; MANAGEMENT; UPDATE; POTENT; PHASE; TRIAZOLOTHIADIAZINES; COMBINATION; DERIVATIVES; DEFINITION;
D O I
10.1016/j.molstruc.2024.141129
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Series of 1,2,4-triazole and condensed triazole derivatives carrying thiophene moieties have synthesized. The compounds were characterized using 1H NMR, 13C NMR and ESI-MS spectrometry. The synthesized compounds were tested for inhibitory activity against a panel of pathogenic Gram-positive and Gram-negative bacteria, as well as pathogenic fungal strains. Additionally, the anti-proliferative activity was evaluated against four human cancer cell lines. The 7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine analogue 6c and the [1,2,4]triazolo[3,4-b] [1,3,4]thiadiazole 5c were found to possess most potent anti-proliferative and antibacterial activities, respectively. The crystal structures of three representative compounds 4b, 4c and 5e was studied by single crystal X ray diffraction. Compounds 4b and 4c crystallized in the monoclinic system (P21/c) with two molecules in the asymmetric unit, and both showed similar crystal packing. However, differences were obtained in their intermolecular interactions and molecular dimers. The crystal structure of 4b is stabilized by N-H & sdot;& sdot;& sdot;N, C-H & sdot;& sdot;& sdot;N/S/pi and pi-stacking interactions. In contrast, 4c exhibits similar stabilizing interactions but also includes two sigma-hole interactions such as S & sdot;& sdot;& sdot;N chalcogen bond and type II Cl & sdot;& sdot;& sdot;Cl halogen bond. Compound 5e also crystallized in the monoclinic system but in the C2/c space group with two crystallographically independent molecules, and its structure is stabilized by intermolecular C-H & sdot;& sdot;& sdot;N/S/pi and pi-stacking interactions, along with C-H & sdot;& sdot;& sdot;Cl interaction and two sigma-hole (S & sdot;& sdot;& sdot;N chalcogen and N & sdot;& sdot;& sdot;N pnictogen bonds) interactions. Hirshfeld surface analysis was performed to examine the nature of intermolecular interactions and their contributions to the crystal packing in 4b, 4c and 5e. The most potent antibacterial compound 6c was subjected to molecular docking with the DNA gyrase of S. aureus, while the most effective anti-proliferative agent 5c was docked with the human CDK2 target. The molecular docking results showed that these compounds can bind to their respective targets and interact with key active site residues.
引用
收藏
页数:16
相关论文
共 84 条
  • [1] Definition of the chalcogen bond (IUPAC Recommendations 2019)
    Aakeroy, Christer B.
    Bryce, David L.
    Desiraju, Gautam
    Frontera, Antonio
    Legon, Anthony C.
    Nicotra, Francesco
    Rissanen, Kari
    Scheiner, Steve
    Terraneo, Giancarlo
    Metrangolo, Pierangelo
    Resnati, Giuseppe
    [J]. PURE AND APPLIED CHEMISTRY, 2019, 91 (11) : 1889 - 1892
  • [2] PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA
    Adasme, Melissa F.
    Linnemann, Katja L.
    Bolz, Sarah Naomi
    Kaiser, Florian
    Salentin, Sebastian
    Haupt, V. Joachim
    Schroeder, Michael
    [J]. NUCLEIC ACIDS RESEARCH, 2021, 49 (W1) : W530 - W534
  • [3] Vision on Synthetic and Medicinal Facets of 1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine Scaffold
    Aggarwal, Ranjana
    Hooda, Mona
    Kumar, Prince
    Sumran, Garima
    [J]. TOPICS IN CURRENT CHEMISTRY, 2022, 380 (02)
  • [4] An insight on medicinal attributes of 1,2,4-triazoles
    Aggarwal, Ranjana
    Sumran, Garima
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 205
  • [5] Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study
    Ahn, Jin-Hee
    Lee, Jeeyun
    Park, Changhee
    Beom, Seung-Hoon
    Kim, Seung Hyun
    Lee, Young Han
    Yun, Kum-Hee
    Kim, Jeung Eun
    Baek, Wooyeol
    Han, Yoon Dae
    Kim, Sang Kyum
    Ryu, Hyang Joo
    Jung, Inkyung
    Lee, Joohee
    Yoon, Hong In
    Kim, Hyo Song
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1457 - 1465
  • [6] Significance of Triazole in Medicinal Chemistry: Advancement in Drug Design, Reward and Biological Activity
    Ajmal, Mohammad
    Mahato, Arun Kumar
    Khan, Mausin
    Rawat, Shivani
    Husain, Asif
    Almalki, Emad Bakheet
    Alzahrani, Mohammed Ahmed
    Haque, Anzarul
    Hakme, Mohammed Japer Mohammed
    Albalawi, Ahmed Suleman
    Rashid, Mohammad
    [J]. CHEMISTRY & BIODIVERSITY, 2024, 21 (07)
  • [7] Insights into the nature of weak noncovalent interactions in 3-(4-fluoropheny1)-6-(2-fluoropheny1)-1,2,4-triazolo[3,4-b][1,3,4] thiadiazole, a potential bioactive agent: X-ray, QTAIM and molecular docking analysis
    Al-Wahaibi, Lamya H.
    Akilandeswari, Gopalan
    Anusha, Ravisankar
    Al-Shaalan, Nora H.
    Alkmali, Omkulthom M.
    El-Emam, Ali A.
    Percino, Judith M.
    Thamotharan, Subbiah
    [J]. JOURNAL OF MOLECULAR STRUCTURE, 2019, 1183 : 331 - 341
  • [8] Determination of minimum inhibitory concentrations
    Andrews, JM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 5 - 16
  • [9] A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer
    Barni, Sandro
    Ghidini, Antonio
    Coinu, Andrea
    Borgonovo, Karen
    Petrelli, Fausto
    [J]. ANTI-CANCER DRUGS, 2014, 25 (10) : 1122 - 1128